OCX - Mergers and acquisitions

Echelon Diagnostics, Inc., a leading provider of genomic healthcare AI imaging and big data solutions, today announced a strategic collaboration with Oncocyte Corporation (NYSE:OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum. The two companies will work together to develop analytical software that can scale to support the commercial expansion of Oncocyte's tests and solutions that may help diagnosis and treatment of cancer, leading to improved patient outcomes and reducing the overall cost of care. "EchelonDx was the right partner to help us build the software solution that allows us to scale an

Gruppo Oncologico del Nord Ovest, a Leading European Clinical Trials Group, Conducts Independent Investigator-Sponsored Clinical Trials for Pharmaceutical Targeted and Immune Therapies If Successful, Oncocyte's DetermaIO Test for Immune Therapy Response Prediction Will Be Validated in a Fifth Tumor Type, Strengthening the Potential for Pan-Cancer Utility IRVINE, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced a strategic collaboration with Gruppo Oncologico del Nord-Ovest (GONO Foundation) of Pisa,

Oncocyte's Nashville CLIA lab now offers the Therascreen RGQ KRAS test Addition of the Therascreen RGQ KRAS test strengthens Oncocyte's one-stop shop offering for lung cancer treatment decisions IRVINE, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, has signed an agreement with QIAGEN N.V. to support the launch of Amgen's LUMAKRAS (Sotorasib). QIAGEN is the leading global provider of "Sample-to-Insight" solutions that enable customers to gain valuable molecular insights from tissue samples. LUMAKRAS™ (Sotorasib) is appro

Coverage policy for transplant rejection monitoring establishes a simplified and accelerated pathway for Medicare coverage of Chronix's solid organ transplant rejection monitoring test Oncocyte's newly acquired IP creates solid foundation for blood-based monitoring for cancer recurrence as well as establishes differentiated, patented product offering for potential partner in $3.5B Global Transplant Rejection Diagnostic Market IRVINE, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, announced that that a pathway for future Me

IRVINE, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that it will release its financial and operating results for the first quarter ended March 31, 2021, on Monday, May 17, 2021, after the close of the U.S. financial markets. The Company will host a conference call on Monday, May 17, 2021, at 4:30 pm ET / 1:30 pm PT to discuss the results along with recent corporate developments. The dial-in number in the U.S./Canada is 877-407-9716; for international participants, the number is 201-493-6779. For all calle

IRVINE, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, will be presenting new data at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held virtually from June 4-8, 2021. The presentation will feature data from a study of Oncocyte's novel predictor of immunotherapy response, DetermaIO™, demonstrating test performance in renal cell cancer. "We look forward to presenting these new data which demonstrate DetermaIO, our gene expression-based test which identifies likely immunotherapy responders versus n

Oncocyte gains proprietary capabilities for immune therapy monitoring and transplant rejection testing, both from a standard blood sample Oncocyte's technologies may provide more precision to the selection of appropriate immune therapies and monitoring for treatment response in real time allowing physicians to personalize treatment more effectively Establishes a European beachhead to launch Oncocyte's full suite of tests IRVINE, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, has completed its acquisition of Chronix Bio

DetermaRx commercialization momentum continues with 36% sample growth and 58% revenue growth compared to Q3 2020 On track to launch DetermaIO™ in 2021 for immune therapy selection Scheduled to present data at 2021 American Association for Cancer Research (AACR) Annual Meeting that supports DetermaIO’s potential pan-cancer applicability Strengthened balance sheet to support ramping commercialization of Oncocyte’s broadening product portfolio Conference call scheduled for 4:30 P.M. EDT IRVINE, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers